Myocardial ATP depletion detected noninvasively predicts sudden cardiac death risk in patients with heart failure.

Abstract

BACKGROUNDSudden cardiac death (SCD) remains a worldwide public health problem in need of better noninvasive predictive tools. Current guidelines for primary preventive SCD therapies, such as implantable cardioverter defibrillators (ICDs), are based on left ventricular ejection fraction (LVEF), but these guidelines are imprecise: fewer than 5% of ICDs deliver lifesaving therapy per year. Impaired cardiac metabolism and ATP depletion cause arrhythmias in experimental models, but to our knowledge a link between arrhythmias and cardiac energetic abnormalities in people has not been explored, nor has the potential for metabolically predicting clinical SCD risk.METHODSWe prospectively measured myocardial energy metabolism noninvasively with phosphorus magnetic resonance spectroscopy in patients with no history of significant arrhythmias prior to scheduled ICD implantation for primary prevention in the setting of reduced LVEF (≤35%).RESULTSBy 2 different analyses, low myocardial ATP significantly predicted the composite of subsequent appropriate ICD firings for life-threatening arrhythmias and cardiac death over approximately 10 years. Life-threatening arrhythmia risk was approximately 3-fold higher in patients with low ATP and independent of established risk factors, including LVEF. In patients with normal ATP, rates of appropriate ICD firings were several-fold lower than reported rates of ICD complications and inappropriate firings.CONCLUSIONTo the best of our knowledge, these are the first data linking in vivo myocardial ATP depletion and subsequent significant arrhythmic events in people, suggesting an energetic component to clinical life-threatening ventricular arrhythmogenesis. The findings support investigation of metabolic strategies that limit ATP loss to treat or prevent life-threatening cardiac arrhythmias and herald noninvasive metabolic imaging as a complementary SCD risk stratification tool.TRIAL REGISTRATIONClinicalTrials.gov NCT00181233.FUNDINGThis work was supported by the DW Reynolds Foundation, the NIH (grants HL61912, HL056882, HL103812, HL132181, HL140034), and Russell H. Morgan and Clarence Doodeman endowments at Johns Hopkins.

• Authors: T Jake Samuel, Shenghan Lai, Michael Schär, Katherine C Wu, Angela M Steinberg, An-Chi Wei, Mark E Anderson, Gordon F Tomaselli, Gary Gerstenblith, Paul A Bottomley, Robert G Weiss
• Journal: JCI insight (JCI Insight) Vol. 7 Issue 12 (06 22 2022) ISSN: 2379-3708 [Electronic] United States
• PMID: 35579938 (Publication Type: Journal Article, Observational Study, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)

Chemical References

• Adenosine Triphosphate

Topics

• Adenosine Triphosphate (analysis)
• Arrhythmias, Cardiac
• Death, Sudden, Cardiac (etiology, prevention & control)
• Heart Failure (complications)
• Humans
• Myocardium
• Risk Factors
• Stroke Volume
• Ventricular Function, Left